Modulation of Regulatory T-Cell and B-Cell Lymphocytes for the Treatment of Autoimmune and Other Disease Indications
Posted Sep 27 2012 8:00pm
Description of Invention: A method of modulating the immune response by affecting the activity of the regulatory lymphocytes through targeting of the Hepatitis A Virus receptor 1 (HAVCR1) receptor. This methodology can be developed for the treatment of autoimmune diseases, allergies, prevention of transplant rejection, and incorporated into therapeutic strategies for cancer.
Regulatory lymphocytes, such as regulatory T-cells (Tregs) and B-cells (Bregs), play a significant role in suppressing and controlling immune responses to antigens, including allergens and self-antigens that induce autoimmune diseases. The Tregs and Bregs also control the immune responses to microbial pathogens thereby limiting excessive damage to tissue. HAVCR1 is expressed on these regulatory lymphocytes and functions as a master regulator of these cells.
Treatment of Autoimmune Diseases
Treatment of Allergies
Prevention of Rejection of Allogenic Transplants
Stimulate Response to Vaccines (adjuvant)
Advantages: Can be used to target multiple disease states.
Collaborative Research Opportunity: The Center for Biologics Evaluation and Research, Laboratory of Emerging Pathogens, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize targeting of HAVCR1 to control Treg and Breg function in human diseases. For collaboration opportunities, please contact Gerardo Kaplan at firstname.lastname@example.org .
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5018 Fax: 301-402-0220